GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...
GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...
GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...
GSK's Penmenvy vaccine is set to transform adolescent immunisation against meningococcal disease in the US, streamlining protection with fewer doses...
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...
GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...
GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...
GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...
GSK's Penmenvy vaccine is set to transform adolescent immunisation against meningococcal disease in the US, streamlining protection with fewer doses...
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...
GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
